PhaseRx (PZRX) IPO Opens Up 10%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PhaseRx Announces Pricing of Initial Public Offering
May 17, 2016 9:19 PM EDTSEATTLE, May 17, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biotechnology company focused on developing mRNA therapeutics to treat orphan liver diseases, today announced the pricing of its initial public offering of 3,700,000 shares of common stock at an initial public offering price of $5.00 per share for an aggregate offering of $18.5 million, before underwriting discounts and commissions. In addition, PhaseRx has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock at the initial public offering price to cover over-allotments, if any.... More
